Virginia Pierce
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
150
Citations
3,347
Est. group size
~2
Recurring co-author estimate
Active years
51
Publishing since 1976
Typically publishes in teams of ~8 · 34% small-team papers (≤3 authors) · across 34 venues
- LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting
PLoS Pathogens · 2026
- Antimicrobial activity of sulbactam-durlobactam against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025)
Microbiology Spectrum · 2026
- LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- P-1215. In vitro activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates from wound and urinary tract sources: ACNBio Study 2023-2025
Open Forum Infectious Diseases · 2026
- Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025)
The Open Repository - Binghamton (Binghamton University) · 2026
- Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
Cell Reports · 2025
- Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains isolated from respiratory and bloodstream sources: results from ACNBio study
Antimicrobial Agents and Chemotherapy · 2025
- First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in <i>Pseudomonas aeruginosa</i>
Clinical Infectious Diseases · 2025
- Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
Cell Reports · 2025
- The carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales
mBio · 2025
- Ventilator-associated pneumonia biomarker evaluation (VIBE) study: protocol for a prospective, observational, case-cohort study
BMJ Open · 2025
- Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- The Growing Threat of NDM-Producing <i>Escherichia coli</i> With Penicillin-Binding Protein 3 Mutations in the United States—Is There a Potential Role for Durlobactam?
Clinical Infectious Diseases · 2024
- How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice
Clinical Infectious Diseases · 2024
- Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test
Journal of Clinical Microbiology · 2024
- Open Forum Infectious Diseases×9
- Clinical Infectious Diseases×7
- Journal of Clinical Microbiology×6
- bioRxiv (Cold Spring Harbor Laboratory)×6
- medRxiv×5
- Paul Lephart
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Qing Wu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Michael A. Bachman
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Jason M. Pogue
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Caitlyn L. Holmes
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile